LCD-L34061
Document details
Summary
The implementation of the new LCD for SCODI may impact billing procedures and reimbursement rates for ophthalmic diagnostic imaging. Practices should review the updated guidelines closely to ensure coNew LCD for SCODI impacts billing and reimbursement procedures.
Affected codes
ICD-10-CM
Affected specialty
Ophthalmology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34061&ver=25CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-BLA761530 · Ophthalmology
LUMVOA (veligrotug) was approved on June 26, 2026 as a new molecular entity administered intravenously, placing it squarely in the Part B billing pathway as a provider-administered injectable. As a br
View alertPolicy FDA-NDA021980 · Ophthalmology
Fluorescite (Fluorescein Sodium) is approved as an injectable drug, which suggests it will qualify for a J-code assignment for Medicare billing. As an injectable and likely high-cost therapy, it may b
View alertPolicy FDA-BLA761480 · Ophthalmology
The billing pathway for RANLUSPEC cannot be determined until the FDA label publishes. Billing teams should verify against the label for the final route of administration and associated billing details
View alertPolicy LCD-L34760 · Ophthalmology
The new LCD on SCODI by WPS introduces specific guidelines that could impact the billing processes for ophthalmic diagnostic imaging services. Practices may need to adjust their coding and ensure comp
View alert